Open Clinical Trials
|
Prostate
|
| 10TASQ10 |
A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate-Resistant Prostate Cancer
|
TAK-700
pre-chemo |
A Phase III trial of TAK-700 (antiandrogen) for patients with castration resistant prostate cancer who are chemo-naive. |
| TAK-700 post-chemo |
A Phase III trial of TAK-700 (antiandrogen) for patients with castration resistant prostate cancer who failed 1st line Taxane chemotherapy. |
|
Non-Hodgkins Lymphoma
|
| CAL-101 |
A Phase II Study to Assess the Efficacy and Safety of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents
|
|
Breast
|
| T-DMI |
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
|
| GDC |
A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
|
|
Phase I
|
| FAK-113517 |
A Phase I Open-Label Dose-Escalation Study of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Subjects with Solid Tumours
|
| FGF-4547 |
A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Malignancies
|
| ROMI–002 |
A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Rifampin on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer
|
| ROMI–001 |
A Phase I Open-label, 2-period Study to Evaluate the Influence of Multiple Oral Doses of Ketoconazole on the Single Dose Pharmacokinetics of Romidepsin in Subjects With Advanced Cancer
|
| PI3K- beta inhibitor |
A Phase I/IIa, First Time in Human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumours with PTEN deficiency
|
| BRAF inhibitor |
A Three-Part, Open-Label Study to Evaluate the Effects of Repeat Dose GSK2118436 on the Single Dose Pharmacokinetics of Warfarin and the Effects of Repeat Dose Oral Ketoconazole and Oral Gemfibrozil on the Repeat Dose Pharmacokinetics of GSK2118436 in Subjects with BRAF Mutant Solid Tumours
|
| TORC 1+ 2 inhibitor |
A Phase I/II, multi-center, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the mtor kinase inhibitor cc-223 administered orally to subjects with advanced solid tumors, non-hodgkin lymphoma or multiple myeloma
|
Please also visit http://www.clinicaltrials.gov.
Click here to access the SCRUK Patient Referral document.